The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2010 Financial Results

Thursday, February 10, 2011

ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2010 Financial Results07:35 EST Thursday, February 10, 2011 CAMBRIDGE, Mass (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will hold a live webcast of its quarterly conference call at 8:30 a.m. (ET) on Thursday, February 17, 2011. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. Senior management will discuss the Company's financial results as of December 31, 2010, key corporate objectives and additional corporate activities. The Company will announce highlights of these topics in a press release to be issued before the market opens on February 17, 2011 prior to the conference call. The live webcast can be accessed by visiting the investor relations section of the Company's website at The call can be accessed by dialing 866-730-5768 (domestic) or 857-350-1592 (international) five minutes prior to the start time and providing the pass code 44207546. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks. About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit ARIAD Pharmaceuticals, Inc.Maria E. Cantor, 617-621-2208